Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Engineering an immuno-nanoprodrug: Photo-controlled pyroptosis synergizing with acid-activatable immunometabolic blockade for potent cancer immunotherapy.

Acta pharmaceutica Sinica. B·2026
Same author

Mechanisms and active components of <i>Solanum nigrum</i> in the amelioration of psoriatic lesions.

Frontiers in immunology·2026
Same author

Autophagy-enhanced hybrid pyroptotic vesicles as personalized vaccines for cancer immunotherapy.

Journal of nanobiotechnology·2026
Same author

ACQ-FRET dual-functional near-infrared fluorescent probes for the bioimaging of nanocarriers.

Asian journal of pharmaceutical sciences·2026
Same author

Compound Platycladus orientalis tincture promotes hair regrowth and is associated with hair-cycle progression and Wnt/β-catenin-related signaling.

Journal of ethnopharmacology·2026
Same author

Extracellular vesicles in chronic wound therapy: engineering strategies and advanced delivery systems for enhanced regeneration.

Materials today. Bio·2026

Related Experiment Video

Updated: Jun 23, 2025

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
07:01

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models

Published on: May 10, 2022

1.6K

ROS-responsive MSC-derived Exosome Mimetics Carrying MHY1485 Alleviate Renal Ischemia Reperfusion Injury through

Zhiyu Qian1,2, Xinyue Zhang3, Jiahua Huang4

  • 1Department of Urology, Zhongshan Hospital Fudan University, 170 Fenglin Road, Shanghai 200030, China.

ACS Omega
|June 17, 2024
PubMed
Summary

This study introduces novel mesenchymal stromal/stem cell-derived exosome mimetics (EMs) loaded with an mTOR agonist to combat kidney injury from renal ischemia reperfusion (IR). These MTM-EMs effectively protect kidneys by reducing inflammation, apoptosis, and ferroptosis.

More Related Videos

Renal Ischaemia Reperfusion Injury: A Mouse Model of Injury and Regeneration
12:27

Renal Ischaemia Reperfusion Injury: A Mouse Model of Injury and Regeneration

Published on: June 7, 2014

49.7K
An Effective Mouse Model of Unilateral Renal Ischemia-Reperfusion Injury
05:53

An Effective Mouse Model of Unilateral Renal Ischemia-Reperfusion Injury

Published on: July 15, 2021

6.7K

Related Experiment Videos

Last Updated: Jun 23, 2025

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
07:01

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models

Published on: May 10, 2022

1.6K
Renal Ischaemia Reperfusion Injury: A Mouse Model of Injury and Regeneration
12:27

Renal Ischaemia Reperfusion Injury: A Mouse Model of Injury and Regeneration

Published on: June 7, 2014

49.7K
An Effective Mouse Model of Unilateral Renal Ischemia-Reperfusion Injury
05:53

An Effective Mouse Model of Unilateral Renal Ischemia-Reperfusion Injury

Published on: July 15, 2021

6.7K

Area of Science:

  • Biomaterials Science
  • Regenerative Medicine
  • Nephrology

Background:

  • Renal ischemia reperfusion (IR) injury is a significant cause of kidney damage after surgeries like transplantation.
  • Current mesenchymal stromal/stem cell (MSC) therapies show limitations in addressing cell death associated with renal IR.
  • Inflammation, apoptosis, and ferroptosis are key pathological processes in renal IR injury.

Purpose of the Study:

  • To develop novel MSC-derived exosome mimetics (EMs) engineered to deliver a mammalian target of the rapamycin (mTOR) agonist.
  • To evaluate the therapeutic efficacy of these modified EMs (MTM-EMs) in protecting against renal IR injury.
  • To investigate the synergistic protective effects of EMs and mTOR agonists on renal IR.

Main Methods:

  • Preparation of thioketal-modified MSC-derived exosome mimetics (EMs) carrying an mTOR agonist (MHY1485).
  • In vivo assessment of MTM-EMs in a renal IR injury model.
  • Evaluation of inflammatory markers, apoptosis, and ferroptosis in kidney tissues.

Main Results:

  • MTM-EMs successfully delivered the mTOR agonist and bioactive molecules to IR kidney areas.
  • Synergistic protection was observed, with MTM-EMs significantly alleviating inflammation, apoptosis, and ferroptosis.
  • The treatment demonstrated a marked improvement in renal function post-IR injury.

Conclusions:

  • MSC-derived exosome mimetics engineered with an mTOR agonist (MTM-EMs) offer a promising therapeutic strategy for renal IR injury.
  • This approach effectively mitigates key pathological mechanisms including inflammation, apoptosis, and ferroptosis.
  • MTM-EMs represent a novel and effective biomaterial for treating kidney damage in IR conditions.